Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System
SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise
Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure
Merck signs $3bn deal for Kate Bingham-backed eye disease biotechRead More
SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion
Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation
QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
- 8 June 2023Portfolio NewsPulmocide Announces Expansion of Management Team
- 5 June 2023Portfolio NewsImbria Pharmaceuticals Completes Enrollment in Phase 2 IMPROVE-HCM Trial of Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy
- 15 May 2023Portfolio NewsTherini Bio Initiates First-In-Human Dosing in Phase 1 Trial of THN391, a Fibrin-Targeting Therapeutic Candidate for Alzheimer’s Disease
- 1 May 2023Portfolio NewsAstellas Pharma buys Iveric Bio for $5.9 billion
- 27 April 2023Portfolio NewsTherini Bio Raises $36M Series A Financing to Develop Fibrin-Targeted Therapies for Neurodegenerative and Retinal Diseases
- 28 March 2023Portfolio NewsBicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates
- 28 March 2023Portfolio NewsPrilenia Achieves Last Patient Last Visit in Phase 3 PROOF-HD Clinical Study for Huntington’s Disease
- 6 March 2023Portfolio NewsEyeBio Announces First Asset in Innovative Pipeline of Retinal Disease Treatments and Appoints Industry Leaders to Executive Team
- 23 February 2023Portfolio NewsPrilenia Announces Topline Results for Pridopidine in Phase 2 ALS Study
- 8 February 2023Portfolio NewsNimbus Therapeutics Announces Closing of Takeda's Acquisition of TYK2 Subsidiary
- 24 January 2023SV NewsBritain is losing its chance to become a life sciences superpower
- 16 January 2023SV NewsBritish Patient Capital and Mubadala Invest in SV Biotech Crossover Opportunities Fund